Transcode Therapeutics Inc (RNAZ) Stock Price, Quote & News

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology

Sector: Healthcare

Phone: 857-837-3099

Website: www.transcodetherapeutics.com

Address:

6 Liberty Square, Suite 2382, Boston, United States

d_risk Aug. 16 at 11:16 PM

$RNAZ - Transcode Therapeutics, Inc. - 10Q - Updated Risk Factors RNAZ’s latest 10-Q highlights urgent capital needs with cash down to $7.4M, warns of possible restructuring or total loss for stockholders, and flags new risks from global economic uncertainty and potential adverse tax law changes. #Biotechnology #TaxLaw #EconomicUncertainty #Restructuring #CapitalRisk 🟢 Added 🟠 Removed https://d-risk.ai/RNAZ/10-Q/2025-08-14

0 · Reply

rock_it_stocks Aug. 15 at 5:06 PM

$RNAZ Confirmed.

0 · Reply

Zeusgodmd Aug. 15 at 11:54 AM

$RNAZ Goldman saks on board a little bigger name and piece of the pie

1 · Reply

Hovius Aug. 15 at 11:50 AM

$RNAZ How Anson Funds created a fake Disney website and made $100 million by ripping off U.S. investors They seem legit…

0 · Reply

Hovius Aug. 15 at 11:44 AM

$RNAZ Police Raid Moez Kassam’s House & MMTLP Lawsuit Causing Anson Funds to Panic Nice guy…

1 · Reply

wazd Aug. 15 at 1:13 AM

$RNAZ lol they still scamming people? 😎

0 · Reply

Vedran1 Aug. 14 at 9:48 PM

$RNAZ In 10-Q Filing today: "... Nasdaq Listing On June 2, 2025, we received a letter from the Nasdaq Stock Market (“Nasdaq”) notifying us that we were deemed in compliance with Nasdaq Listing Rule 5550(a)(2), requiring that a company maintain a minimum closing bid price of $1.00 per share. As a result, and subject to our remaining in compliance with Nasdaq listing requirements, our stock will continue to be listed on the Nasdaq. ..." https://ir.transcodetherapeutics.com/sec-filings/sec-filing/10-q/0001558370-25-011571

1 · Reply

ioiioiioiioi Aug. 14 at 3:48 AM

$RNAZ When is the earnings call scheduled? They said it would be in August, but there’s been no news.

1 · Reply

dishenghk Aug. 12 at 2:26 PM

$RNAZ Any News?

1 · Reply

Scoty_D Aug. 12 at 12:32 PM

$RNAZ

0 · Reply

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 8, 2025, 8:05 AM EDT - 3 months ago

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 5, 2025, 5:07 PM EDT - 3 months ago

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 3 months ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 1, 2025, 9:01 AM EDT - 3 months ago

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

Apr 21, 2025, 4:37 PM EDT - 4 months ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Mar 27, 2025, 4:37 PM EDT - 5 months ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Mar 25, 2025, 6:24 PM EDT - 5 months ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

Mar 23, 2025, 11:11 PM EDT - 5 months ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 13, 2025, 7:47 AM EDT - 5 months ago

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Feb 25, 2025, 4:15 PM EST - 6 months ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

Feb 6, 2025, 8:00 AM EST - 6 months ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

Jan 14, 2025, 8:00 AM EST - 7 months ago

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Jan 7, 2025, 8:00 AM EST - 7 months ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Dec 18, 2024, 8:00 AM EST - 8 months ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Nov 29, 2024, 4:25 PM EST - 9 months ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Nov 27, 2024, 7:00 AM EST - 9 months ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Nov 5, 2024, 7:00 AM EST - 10 months ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Sep 17, 2024, 7:00 AM EDT - 11 months ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Sep 5, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Jul 24, 2024, 4:05 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Jul 22, 2024, 10:30 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Jul 22, 2024, 4:07 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

May 29, 2024, 9:15 AM EDT - 1 year ago

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

May 13, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Open Letter to Shareholders

Apr 15, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Apr 3, 2024, 9:10 AM EDT - 1 year ago

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Mar 28, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Mar 11, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Mar 6, 2024, 4:15 PM EST - 1 year ago

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Feb 20, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Jan 31, 2024, 4:05 PM EST - 1 year ago

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

Jan 29, 2024, 8:30 AM EST - 1 year ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Jan 22, 2024, 4:45 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

Jan 18, 2024, 1:27 PM EST - 1 year ago

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Jan 12, 2024, 4:05 PM EST - 1 year ago

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

Jan 11, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 4, 2024, 8:05 AM EST - 1 year ago

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

Dec 12, 2023, 8:30 AM EST - 1 year ago

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Dec 5, 2023, 9:00 AM EST - 1 year ago

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

Dec 4, 2023, 4:10 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 30, 2023, 2:53 PM EST - 1 year ago

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 14, 2023, 4:30 PM EST - 1 year ago

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

Oct 30, 2023, 4:33 PM EDT - 1 year ago

TransCode Therapeutics Withdraws Public Offering

Oct 27, 2023, 8:00 AM EDT - 1 year ago

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

Oct 26, 2023, 4:19 PM EDT - 1 year ago

TransCode Therapeutics Announces Public Offering of Common Stock

Oct 26, 2023, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

Oct 24, 2023, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

Oct 16, 2023, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

Sep 28, 2023, 4:02 PM EDT - 2 years ago

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

d_risk Aug. 16 at 11:16 PM

0 · Reply

rock_it_stocks Aug. 15 at 5:06 PM

$RNAZ Confirmed.

0 · Reply

Zeusgodmd Aug. 15 at 11:54 AM

$RNAZ Goldman saks on board a little bigger name and piece of the pie

1 · Reply

Hovius Aug. 15 at 11:50 AM

$RNAZ How Anson Funds created a fake Disney website and made $100 million by ripping off U.S. investors They seem legit…

0 · Reply

Hovius Aug. 15 at 11:44 AM

$RNAZ Police Raid Moez Kassam’s House & MMTLP Lawsuit Causing Anson Funds to Panic Nice guy…

1 · Reply

wazd Aug. 15 at 1:13 AM

$RNAZ lol they still scamming people? 😎

0 · Reply

Vedran1 Aug. 14 at 9:48 PM

1 · Reply

ioiioiioiioi Aug. 14 at 3:48 AM

$RNAZ When is the earnings call scheduled? They said it would be in August, but there’s been no news.

1 · Reply

dishenghk Aug. 12 at 2:26 PM

$RNAZ Any News?

1 · Reply

Scoty_D Aug. 12 at 12:32 PM

$RNAZ

0 · Reply

yomamastonks Aug. 12 at 2:18 AM

$RNAZ do you have to be trans to buy this?

1 · Reply

Zeusgodmd Aug. 10 at 8:51 PM

$RNAZ I’m sure the data is being collected and they will share should be a big day.

2 · Reply

ioiioiioiioi Aug. 10 at 5:37 PM

$RNAZ The earnings call is on August 21. I wonder if the stock will rise before then… I just want to get out.😭

0 · Reply

Scrubinski Aug. 6 at 5:07 PM

$RNAZ I don't understand the MM for this stock. Bid of 11.2 ask of 11.49, but a price of 10.93?

0 · Reply

ZhaoSonsWealth Aug. 6 at 12:06 AM

IBG watch this one! 🚨🚨 100m+ volume recently and now 20% shorted Low float this this don’t stay quiet forever. No dilution. No crowd. Just sitting at the launchpad. One catalyst merger, rumor, volume and this thing erupts. These are the setups that change accounts. $SLNO $RNAZ $SHPH $LUNR

0 · Reply

bMagic69 Aug. 5 at 10:05 PM

$GUTS $RNAZ offering has been active since March.

1 · Reply

casedoog Aug. 5 at 9:58 PM

$GUTS that’s gotta be close to a record for quickest offering after press release. $RNAZ was probably a few minutes quicker, but that was quick. Jimmy John’s fast. Sorry to all the bulls bag holding. I scalped $.18 a share and never looked back.

0 · Reply

Tradingforfunz Aug. 5 at 8:44 PM

$RNAZ to 15

0 · Reply

Scoty_D Aug. 5 at 3:59 PM

$RNAZ

0 · Reply

StockRedBaron Aug. 5 at 10:53 AM

$ACON Absolutely Sir - tiny 582K float - MANY companies with waaay less than Aclarion have had 400% runs or more...Just see $RNAZ's history for example. Or any number of fake China companies. Aclarion's PR today says it all!

0 · Reply

swingzking Aug. 1 at 3:48 PM

$RNAZ Super thin name acting up. Chart supports a pump from here. Lets see

1 · Reply

Scoty_D Jul. 31 at 4:31 AM

$RNAZ It's time .......

0 · Reply

Market Cap	9.00M
Revenue (ttm)	0.00
Net Income (ttm)	-16.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	15,600
Avg Vol	116,774
Day's Range	N/A - N/A
Shares Out	834,000.00
Stochastic %K	32%
Beta	1.46
Analysts	Strong Buy
Price Target	$10.00